Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
40287 studies found for:    Open Studies | Senior
Show Display Options
Rank Status Study
1 Recruiting Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification
Condition: Breast Cancer
Interventions: Drug: Carvedilol;   Other: placebo
2 Unknown  Pharmacogenomic Study to Predict Antidepressant Responsiveness in Depressed Patients
Conditions: Depression;   Adverse Reaction to Drug
Interventions: Drug: SSRI class antidepressant;   Drug: non-SSRI class antidepressant
3 Recruiting Incidence of Febrile Neutropenia
Condition: Chemotherapy-induced Febrile Neutropenia
Intervention:
4 Not yet recruiting Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Vorinostat Velcade Dexamethasone
5 Recruiting Systematic Registration of All Big Toe Prostheses Placed in Ghent University Hospital
Condition: Big Toe Prosthesis
Intervention: Procedure: Registration of all big toe prostheses in Ghent University Hospital
6 Recruiting MRA Therapy Versus CPAP Therapy in Moderate OSAS
Condition: Sleep Apnea, Obstructive
Interventions: Device: mandibular repositioning appliance (MRA) (SomnoDent);   Procedure: Continuous positive airway pressure (CPAP)
7 Not yet recruiting Combination of Lenalidomide and Obinutuzumab (GA101) in Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Condition: Leukemia
Interventions: Drug: Lenalidomide;   Drug: Obinutuzumab
8 Recruiting Naive T-Cell Depleted DLI Following Allo Stem Cell Transplant
Condition: Hematological Malignancies
Intervention: Biological: Naive T Cell Depleted Donor Lymphocyte Infusion
9 Recruiting Efficacy Study of IgY (Antibody Against Pseudomonas) in Cystic Fibrosis Patients
Condition: Cystic Fibrosis
Interventions: Drug: IgY;   Drug: Placebo
10 Recruiting Database of All Patients With Microbiologically Proven Mycobacteria Tuberculosis Infection
Condition: Tuberculosis
Intervention:
11 Recruiting Micafungin Versus Fluconazole for Prevention of Invasive Fungal Disease in Living Donor Liver Transplant Recipients
Condition: Liver Transplant Recipient
Interventions: Drug: micafungin;   Drug: Fluconazole
12 Unknown  Dual Antiplatelet Therapy Tailored on the Extent of Platelet Inhibition
Conditions: Unstable Angina;   NSTEMI
Interventions: Drug: comparison of different dosage of clopidogrel;   Drug: doubled therapy
13 Recruiting Combi-Neo Study for Stage IV Melanoma
Conditions: Melanoma;   Malignant Melanoma Stage IV;   Metastatic Melanoma
Interventions: Drug: Dabrafenib;   Drug: Trametinib;   Procedure: Surgery
14 Unknown  Genetic Linkage Study for Hereditary Pancreatitis
Condition: Pancreatitis
Intervention: Procedure: genetic testing
15 Unknown  Step'n Out: A Multisite Trial of Collaborative Behavioral Management for Drug-Involved Parolees
Condition: Substance-Related Disorders
Interventions: Behavioral: Collaborative Behavioral Management;   Procedure: Integrated parole and outpatient addiction treatment
16 Recruiting Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma
Conditions: Multiple Myeloma;   Non-Hodgkin's Lymphoma
Interventions: Drug: Romidepsin;   Drug: Lenalidomide
17 Unknown  Treatment of Patients With Advanced Renal Cancer With a Radio-labeled Antibody, Yttrium-90 Conjugated Chimeric G250
Conditions: Renal Cell Carcinoma;   Kidney Neoplasm;   Renal Cancer;   Kidney Cancer
Intervention: Drug: Yttrium-90 conjugated chimeric G250 (90Y-cG250)
18 Recruiting Comparison Between Endoscopic Stenting and Cholecystojejunostomy for PreoperativeDrainage Before Pancreaticoduodenectomy
Conditions: Periampullary Cancer;   Pancreatic Cancer
Interventions: Procedure: Endoscopic stenting;   Procedure: cholecystojejunostomy
19 Not yet recruiting Study 3: Minocycline Decreases Microglia Activation
Condition: Hypertension
Intervention: Other: Minocycline
20 Recruiting A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)
Conditions: Breast Neoplasms;   BRCA 1 Gene Mutation;   BRCA 2 Gene Mutation
Interventions: Drug: talazoparib;   Drug: Physician's-Choice

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years